Volume Alert - BSX 13.54 Boston Scientific Corp $B
Post# of 122
Posted On: 11/19/2014 1:31:56 PM
Volume Alert - BSX 13.54 Boston Scientific Corp $BSX Hit a high today of 13.68 Closing the day 10:29 at 13.54 -0.14 -1.02% With a day low of 13.52 and a total volume of 1,512,292.
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
Boston Scientific (BSX) Is Water-Logged And Getting Wetter Today
at The Street - 39 mins ago
Trade-Ideas LLC identified Boston Scientific (BSX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
BSX: 13.20 (-0.48)
New Data From Evolve Clinical Program Demonstrate SYNERGY(TM) Bioabsobable Polymer Stent Meets Key Performance Endpoints
PR Newswire - 1 hr 21 mins ago
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).
BSX: 13.20 (-0.48)
Will Boston Scientific (BSX) Stock Be Hurt Today by Johnson & Johnson Lawsuit?
at The Street - Wed Nov 19, 8:03AM CST
Boston Scientific (BSX) is being sued by Johnson & Johnson (JNJ) for several billion dollars relating to a decade old bidding war for device maker Guidant.
BSX: 13.20 (-0.48)
Research and Markets: Global Defibrillator Market 2014-2018: Key Vendors are BIOTRONIK, Boston Scientific, Medtronic, Phillips Healthcare and St. Jude Medical
Business Wire - Wed Nov 19, 6:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrlzsd/global) has announced the addition of the "Global Defibrillator Market 2014-2018" report to their offering.
BSX: 13.20 (-0.48), MDT: 71.81 (-0.66)
Wall Street Breakfast: Dollar General May Have To Divest 4,000+ Stores
Wall Street Breakfast - Seeking Alpha - Wed Nov 19, 5:30AM CST
Economy The Ebola epidemic in west Africa has led mining companies in the region to put expansion plans on hold, delaying the rollout of jobs meant for residents of the countries hardest hit by the virus. ArcelorMittal (NYSE: MT ) has delayed a...
BX: 32.72 (+0.11), KKR: 22.97 (+0.28), BSX: 13.20 (-0.48), JNJ: 108.26 (-0.57), PBR: 9.42 (unch), T: 35.38 (-0.34), DLTR: 62.20 (+0.21), APO: 23.00 (-0.34), SPY: 205.02 (-0.53), TRP: 50.74 (+1.17), GALE: 1.85 (+0.01), DG: 64.18 (-1.99), TMUS: 27.45 (-0.42), PGRE: 18.28 (+18.28), RIO: 46.16 (-1.10), FDO: 77.99 (-0.86), DISH: 73.42 (+5.57), MT: 12.26 (-0.19), GS: 189.65 (+0.01), OME: 11.52 (-0.93), QQQ: 103.26 (-0.42), VZ: 50.52 (-0.70), PETM: 77.11 (+3.49)
Global Defibrillator Market 2014-2018: Key Vendors are BIOTRONIK, Boston Scientific, Medtronic, Phillips Healthcare and St. Jude Medical
M2 - Wed Nov 19, 3:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfq4pf/global) has announced the addition of the "Global Defibrillator Market 2014-2018" report to their offering. One of the key trends in this market is the increase in the use of multifunction defibrillators. Other parameters that can be monitored with the help of the current multifunctional defibrillators include SPO2, blood pressure, and CO2. According to the report, one of the key drivers of this market is the increase in the incidence of cardiac disorders. Cardiac disorders are caused by the increase in cholesterol levels, excessive smoking, and hypertension while a defibrillator is a life-saving device for a person undergoing sudden cardiac arrest. Further, the report states that one of the major challenges that the market faces is the presence of safety concerns associated with the use of defibrillators. Defibrillators such as ICDs are implanted through the MI procedure, which poses the risks of lead dislodgement, movement of the ICD generator out of its proper position, inappropriate shocks leading to pain or other complications, and psychological trauma. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Market Segmentation by End-users 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. 17. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - BIOTRONIK - Boston Scientific - Medtronic - Phillips Healthcare - St. Jude Medical - Asahi Kasei - Defibtech - Exactech - GE Healthcare - Heartsine Technologies - Mindray Medical International - Nihon Kohden - Physio-Control - Schiller - Sorin For more information visit http://www.researchandmarkets.com/research/gfq4pf/global
BSX: 13.20 (-0.48), MDT: 71.81 (-0.66), STJ: 64.02 (-0.93), MR: 30.95 (+0.19)
J&J, Boston Scientific $5B trial to begin Thursday
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 1:44AM CST
BSX: 13.20 (-0.48), JNJ: 108.26 (-0.57)
Watch for Boston Scientific to Potentially Pullback After Gaining 2.24% Yesterday
Comtex SmarTrend(R) - Tue Nov 18, 4:01PM CST
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $13.35 to a high of $13.76. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $13.55 on volume of 27.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 13.20 (-0.48)
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 2.24% Gain
Comtex SmarTrend(R) - Tue Nov 18, 4:00PM CST
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $13.35 to a high of $13.76. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $13.55 on volume of 27.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 13.20 (-0.48)
Watch Out: Barbarians At The Gate For Boston Scientific (BSX)
at The Street - Tue Nov 18, 2:28PM CST
Trade-Ideas LLC identified Boston Scientific (BSX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
BSX: 13.20 (-0.48)
Boston Scientific's Symphion System Marks 1st US Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 1:50PM CST
Boston Scientific's (BSX) Symphion System incorporates breakthrough technologies that jointly work toward efficient uterine tissue removal with greater patient safety.
BSX: 13.20 (-0.48), ICUI: 82.93 (-2.63), GWPH: 80.04 (-0.46), OSUR: 8.81 (-0.08)
Medtronic (MDT) Posts In Line Earnings, Revenues Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 11:21AM CST
Medtronic Inc.'s (MDT) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents.
BSX: 13.20 (-0.48), MDT: 71.80 (-0.67), ABAX: 53.97 (-0.64), COV: 97.56 (-0.53)
Advanced Remote Patient Monitoring Systems Market Report: 2014 Edition
M2 - Tue Nov 18, 9:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/f348f9/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 7th Edition" report to their offering. For their potential to reduce healthcare costs and improve patient outcomes, patient monitoring systems with advanced capabilities are among the fastest-growing devices in terms of revenue growth. In recent years, there's been demand from healthcare organizations for monitors with remote reporting functions and EMR transfer. Advanced Remote Patient Monitoring Systems, is a comprehensive study on the patient monitoring industry, including the advanced system with remote and wireless capability to includes patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. For the most part, devices covered in this report can: 1) provide monitoring information beyond a patient room; and 2) provide data for an EMR system or are expected to add such features within the forecast period. This report provides complete market sizes and revenue breakouts for the important segments of the advanced monitoring market. For the purpose of this report, three general areas of advanced patient monitoring are covered. - Blood Management and Function Monitors - Glucose Monitor, Blood Pressure Monitor, PT/INR, Other - Cardiac Event and Function Monitors - Cardiac Event, EKG/ECG - Neurological Event Monitors - Respiratory Function Monitors - Anesthesia - General - Sleep Apnea There are a considerable number of companies offering some form of wireless and remote technologies, patient data processing applications and equipment, and EMR data transfer equipment. A select few are profiled in this report including: - Abbott Laboratories - Aerotel Medical Systems - Alere - AMD Global Telemedicine - American TeleCare - AuthentiDate - B. Braun - Baxter - Bosch - Boston Scientific - C.R. Bard - Cardiocom - Carematix - Compumedics . - Covidien - Criticare Systems - Dr?ger Medical - GE Healthcare - Masimo - MEDTRONIC - Mindray - Omron Healthcare - OSI Systems - PHILIPS HEALTHCARE - Roche - Schiller - Second Opinion Telemedicine . - Smiths Medical - St. Jude Medical - Welch Allyn For more information visit http://www.researchandmarkets.com/research/f3...ced_remote
CMD: 70.45 (-0.68), BSX: 13.20 (-0.48), ABT: 43.55 (-0.15), MDT: 71.80 (-0.67), STJ: 64.02 (-0.93), OSIS: 68.25 (-0.35)
Watch for Shares of Boston Scientific (BSX) to Approach Resistance at $13.51
Comtex SmarTrend(R) - Tue Nov 18, 8:59AM CST
Boston Scientific (NYSE:BSX) has opened bullishly above the pivot of $13.36 today and has reached the first level of resistance at $13.45. Investors may be interested in a cross of the next upside pivot targets of $13.51 and $13.66.
BSX: 13.20 (-0.48)
Why Baxter Has An Attractive Economic Castle
Valuentum - at Seeking Alpha - Tue Nov 18, 7:11AM CST
BSX: 13.20 (-0.48), BDX: 129.47 (-1.47), BAX: 72.39 (-0.19)
First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System
PR Newswire - Mon Nov 17, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symphion System combines a self-contained, recirculating fluid management system, direct intrauterine pressure monitoring and bladeless bipolar RF plasma resection to remove uterine tissue. Hysteroscopic removal of symptomatic fibroids and polyps is a minimally invasive surgical technique and intended to be less traumatic to the patient.
BSX: 13.20 (-0.48)
Insider Trading Alerts for Tesla, Globalstar, Boston Scientific, Apple, Yahoo, and Twitter
PR Newswire - Mon Nov 17, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Tesla (NASDAQ:TSLA), Globalstar (NYSEMKT:GSAT), Boston Scientific (NYSE:BSX), Apple (NASDAQ:AAPL), Yahoo! (NASDAQ:YHOO), and Plug Power (NASDAQ
LUG).
BSX: 13.20 (-0.48), YHOO: 51.21 (-0.54), TSLA: 248.59 (-9.11), PLUG: 4.02 (-0.02), TWTR: 39.86 (-0.75), AAPL: 114.94 (-0.53), GSAT: 2.66 (+0.11)
Jury Finds for Four Women in Multi-Million-Dollar Boston Scientific Bellwether Cases, Parker Waichman LLP Comments
PRWeb - Fri Nov 14, 8:30PM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medical devices, comments on a case in which a Florida federal jury found in favor of four women who allege they suffered injuries as a result of Boston Scientific Corp.'s pelvic mesh implant device, the Pinnacle Pelvic Floor Repair Kit. The jury awarded the four women with $26.7 million. The case is Amal Eghnayem et al. v. Boston Scientific Corp., case number 1:14-cv-24061, in the U.S. District Court for the Southern District of Florida.
BSX: 13.20 (-0.48)
Boston Sci loses first federal case over vaginal mesh product
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:08AM CST
BSX: 13.20 (-0.48)
Subcutaneous Implantable Defibrillator Receives Favorable Coding And Payment Designations For 2015
PR Newswire - Thu Nov 13, 4:07PM CST
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System(TM)) will have designated Current Procedural Terminology (CPT®) Category I codes by the American Medical Association (AMA), effective January 1, 2015. The AMA CPT coding system provides U.S. physicians and hospitals with a uniform process for coding medical services. By definition, the CPT I category includes procedures that are widely performed and consistent with contemporary medical practice.
BSX: 13.20 (-0.48)
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
Boston Scientific (BSX) Is Water-Logged And Getting Wetter Today
at The Street - 39 mins ago
Trade-Ideas LLC identified Boston Scientific (BSX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
BSX: 13.20 (-0.48)
New Data From Evolve Clinical Program Demonstrate SYNERGY(TM) Bioabsobable Polymer Stent Meets Key Performance Endpoints
PR Newswire - 1 hr 21 mins ago
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).
BSX: 13.20 (-0.48)
Will Boston Scientific (BSX) Stock Be Hurt Today by Johnson & Johnson Lawsuit?
at The Street - Wed Nov 19, 8:03AM CST
Boston Scientific (BSX) is being sued by Johnson & Johnson (JNJ) for several billion dollars relating to a decade old bidding war for device maker Guidant.
BSX: 13.20 (-0.48)
Research and Markets: Global Defibrillator Market 2014-2018: Key Vendors are BIOTRONIK, Boston Scientific, Medtronic, Phillips Healthcare and St. Jude Medical
Business Wire - Wed Nov 19, 6:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrlzsd/global) has announced the addition of the "Global Defibrillator Market 2014-2018" report to their offering.
BSX: 13.20 (-0.48), MDT: 71.81 (-0.66)
Wall Street Breakfast: Dollar General May Have To Divest 4,000+ Stores
Wall Street Breakfast - Seeking Alpha - Wed Nov 19, 5:30AM CST
Economy The Ebola epidemic in west Africa has led mining companies in the region to put expansion plans on hold, delaying the rollout of jobs meant for residents of the countries hardest hit by the virus. ArcelorMittal (NYSE: MT ) has delayed a...
BX: 32.72 (+0.11), KKR: 22.97 (+0.28), BSX: 13.20 (-0.48), JNJ: 108.26 (-0.57), PBR: 9.42 (unch), T: 35.38 (-0.34), DLTR: 62.20 (+0.21), APO: 23.00 (-0.34), SPY: 205.02 (-0.53), TRP: 50.74 (+1.17), GALE: 1.85 (+0.01), DG: 64.18 (-1.99), TMUS: 27.45 (-0.42), PGRE: 18.28 (+18.28), RIO: 46.16 (-1.10), FDO: 77.99 (-0.86), DISH: 73.42 (+5.57), MT: 12.26 (-0.19), GS: 189.65 (+0.01), OME: 11.52 (-0.93), QQQ: 103.26 (-0.42), VZ: 50.52 (-0.70), PETM: 77.11 (+3.49)
Global Defibrillator Market 2014-2018: Key Vendors are BIOTRONIK, Boston Scientific, Medtronic, Phillips Healthcare and St. Jude Medical
M2 - Wed Nov 19, 3:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfq4pf/global) has announced the addition of the "Global Defibrillator Market 2014-2018" report to their offering. One of the key trends in this market is the increase in the use of multifunction defibrillators. Other parameters that can be monitored with the help of the current multifunctional defibrillators include SPO2, blood pressure, and CO2. According to the report, one of the key drivers of this market is the increase in the incidence of cardiac disorders. Cardiac disorders are caused by the increase in cholesterol levels, excessive smoking, and hypertension while a defibrillator is a life-saving device for a person undergoing sudden cardiac arrest. Further, the report states that one of the major challenges that the market faces is the presence of safety concerns associated with the use of defibrillators. Defibrillators such as ICDs are implanted through the MI procedure, which poses the risks of lead dislodgement, movement of the ICD generator out of its proper position, inappropriate shocks leading to pain or other complications, and psychological trauma. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Market Segmentation by End-users 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. 17. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - BIOTRONIK - Boston Scientific - Medtronic - Phillips Healthcare - St. Jude Medical - Asahi Kasei - Defibtech - Exactech - GE Healthcare - Heartsine Technologies - Mindray Medical International - Nihon Kohden - Physio-Control - Schiller - Sorin For more information visit http://www.researchandmarkets.com/research/gfq4pf/global
BSX: 13.20 (-0.48), MDT: 71.81 (-0.66), STJ: 64.02 (-0.93), MR: 30.95 (+0.19)
J&J, Boston Scientific $5B trial to begin Thursday
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 1:44AM CST
BSX: 13.20 (-0.48), JNJ: 108.26 (-0.57)
Watch for Boston Scientific to Potentially Pullback After Gaining 2.24% Yesterday
Comtex SmarTrend(R) - Tue Nov 18, 4:01PM CST
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $13.35 to a high of $13.76. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $13.55 on volume of 27.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 13.20 (-0.48)
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 2.24% Gain
Comtex SmarTrend(R) - Tue Nov 18, 4:00PM CST
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $13.35 to a high of $13.76. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $13.55 on volume of 27.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 13.20 (-0.48)
Watch Out: Barbarians At The Gate For Boston Scientific (BSX)
at The Street - Tue Nov 18, 2:28PM CST
Trade-Ideas LLC identified Boston Scientific (BSX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
BSX: 13.20 (-0.48)
Boston Scientific's Symphion System Marks 1st US Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 1:50PM CST
Boston Scientific's (BSX) Symphion System incorporates breakthrough technologies that jointly work toward efficient uterine tissue removal with greater patient safety.
BSX: 13.20 (-0.48), ICUI: 82.93 (-2.63), GWPH: 80.04 (-0.46), OSUR: 8.81 (-0.08)
Medtronic (MDT) Posts In Line Earnings, Revenues Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 11:21AM CST
Medtronic Inc.'s (MDT) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents.
BSX: 13.20 (-0.48), MDT: 71.80 (-0.67), ABAX: 53.97 (-0.64), COV: 97.56 (-0.53)
Advanced Remote Patient Monitoring Systems Market Report: 2014 Edition
M2 - Tue Nov 18, 9:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/f348f9/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 7th Edition" report to their offering. For their potential to reduce healthcare costs and improve patient outcomes, patient monitoring systems with advanced capabilities are among the fastest-growing devices in terms of revenue growth. In recent years, there's been demand from healthcare organizations for monitors with remote reporting functions and EMR transfer. Advanced Remote Patient Monitoring Systems, is a comprehensive study on the patient monitoring industry, including the advanced system with remote and wireless capability to includes patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. For the most part, devices covered in this report can: 1) provide monitoring information beyond a patient room; and 2) provide data for an EMR system or are expected to add such features within the forecast period. This report provides complete market sizes and revenue breakouts for the important segments of the advanced monitoring market. For the purpose of this report, three general areas of advanced patient monitoring are covered. - Blood Management and Function Monitors - Glucose Monitor, Blood Pressure Monitor, PT/INR, Other - Cardiac Event and Function Monitors - Cardiac Event, EKG/ECG - Neurological Event Monitors - Respiratory Function Monitors - Anesthesia - General - Sleep Apnea There are a considerable number of companies offering some form of wireless and remote technologies, patient data processing applications and equipment, and EMR data transfer equipment. A select few are profiled in this report including: - Abbott Laboratories - Aerotel Medical Systems - Alere - AMD Global Telemedicine - American TeleCare - AuthentiDate - B. Braun - Baxter - Bosch - Boston Scientific - C.R. Bard - Cardiocom - Carematix - Compumedics . - Covidien - Criticare Systems - Dr?ger Medical - GE Healthcare - Masimo - MEDTRONIC - Mindray - Omron Healthcare - OSI Systems - PHILIPS HEALTHCARE - Roche - Schiller - Second Opinion Telemedicine . - Smiths Medical - St. Jude Medical - Welch Allyn For more information visit http://www.researchandmarkets.com/research/f3...ced_remote
CMD: 70.45 (-0.68), BSX: 13.20 (-0.48), ABT: 43.55 (-0.15), MDT: 71.80 (-0.67), STJ: 64.02 (-0.93), OSIS: 68.25 (-0.35)
Watch for Shares of Boston Scientific (BSX) to Approach Resistance at $13.51
Comtex SmarTrend(R) - Tue Nov 18, 8:59AM CST
Boston Scientific (NYSE:BSX) has opened bullishly above the pivot of $13.36 today and has reached the first level of resistance at $13.45. Investors may be interested in a cross of the next upside pivot targets of $13.51 and $13.66.
BSX: 13.20 (-0.48)
Why Baxter Has An Attractive Economic Castle
Valuentum - at Seeking Alpha - Tue Nov 18, 7:11AM CST
BSX: 13.20 (-0.48), BDX: 129.47 (-1.47), BAX: 72.39 (-0.19)
First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System
PR Newswire - Mon Nov 17, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symphion System combines a self-contained, recirculating fluid management system, direct intrauterine pressure monitoring and bladeless bipolar RF plasma resection to remove uterine tissue. Hysteroscopic removal of symptomatic fibroids and polyps is a minimally invasive surgical technique and intended to be less traumatic to the patient.
BSX: 13.20 (-0.48)
Insider Trading Alerts for Tesla, Globalstar, Boston Scientific, Apple, Yahoo, and Twitter
PR Newswire - Mon Nov 17, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Tesla (NASDAQ:TSLA), Globalstar (NYSEMKT:GSAT), Boston Scientific (NYSE:BSX), Apple (NASDAQ:AAPL), Yahoo! (NASDAQ:YHOO), and Plug Power (NASDAQ
LUG). BSX: 13.20 (-0.48), YHOO: 51.21 (-0.54), TSLA: 248.59 (-9.11), PLUG: 4.02 (-0.02), TWTR: 39.86 (-0.75), AAPL: 114.94 (-0.53), GSAT: 2.66 (+0.11)
Jury Finds for Four Women in Multi-Million-Dollar Boston Scientific Bellwether Cases, Parker Waichman LLP Comments
PRWeb - Fri Nov 14, 8:30PM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medical devices, comments on a case in which a Florida federal jury found in favor of four women who allege they suffered injuries as a result of Boston Scientific Corp.'s pelvic mesh implant device, the Pinnacle Pelvic Floor Repair Kit. The jury awarded the four women with $26.7 million. The case is Amal Eghnayem et al. v. Boston Scientific Corp., case number 1:14-cv-24061, in the U.S. District Court for the Southern District of Florida.
BSX: 13.20 (-0.48)
Boston Sci loses first federal case over vaginal mesh product
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:08AM CST
BSX: 13.20 (-0.48)
Subcutaneous Implantable Defibrillator Receives Favorable Coding And Payment Designations For 2015
PR Newswire - Thu Nov 13, 4:07PM CST
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System(TM)) will have designated Current Procedural Terminology (CPT®) Category I codes by the American Medical Association (AMA), effective January 1, 2015. The AMA CPT coding system provides U.S. physicians and hospitals with a uniform process for coding medical services. By definition, the CPT I category includes procedures that are widely performed and consistent with contemporary medical practice.
BSX: 13.20 (-0.48)
(0)
(0)Boston Scientific Corporation (BSX) Stock Research Links
Scroll down for more posts ▼